Previous Close | 269.38 |
Open | 265.72 |
Bid | 269.97 x 100 |
Ask | 270.13 x 100 |
Day's Range | 265.72 - 271.68 |
52 Week Range | 211.71 - 329.72 |
Volume | |
Avg. Volume | 2,949,077 |
Market Cap | 144.811B |
Beta (5Y Monthly) | 0.60 |
PE Ratio (TTM) | 21.60 |
EPS (TTM) | 12.50 |
Earnings Date | May 02, 2024 |
Forward Dividend & Yield | 9.00 (3.33%) |
Ex-Dividend Date | May 16, 2024 |
1y Target Est | 306.20 |
Stock market investors brace for a big week of earnings and econ as Apple, Amazon, Big Pharma and The Fed all line up to deliver news.
Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R), for the treatment of moderate to severe Thyroid Eye Disease (TED) in adults. TED is a serious, progressive, debilitating and potentially vision-threatening autoimmune disease that can cause proptosis (eye bulging), diplopia
In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]